Social Media Monitoring Report on Hemlibra, a drug by Roche, Inc. for Hemophilia A
Research Study Background
Roche developed drug, Hemlibra (emicizumab) got US FDA marketing approval on 16th Nov 2017 for adult patients with Hemophilia A.
Hemlibra is a bispecific factor IXa- and factor X-directed antibody which was approved on the basis of clinical data from phase III clinical trial where Hemlibra showed significant improvement in hemophilia-related symptoms and physical functioning. The FDA granted application Hemlibra also received Orphan Drug designation.
Roche got Prior marketing authorization for Hemlibra under Priority Review and Breakthrough Therapy designations.
Sentiment Analysis on Hemlibra Drug Approval
Positive: Hemlibra approval was quoted as a landmark breakthrough - “Amazing news for #Hemophilia A #patients ! #Hemlibra approval #FDA #biotech #Pharma”- HCP
Negative: Some were found concerned about Hemlibra safety and commercial session and reflected negatively on social media channels – “Did I miss something or shouldn't the #FDA have held an adcomm session for emicizumab (Hemlibra)? Serious safety issue, black box, Shire toe-to-toe on data. Needed public hearing.”- Journalist
Neutral: Majority of healthcare practitioners were either neutral or positive about the approval and found sharing the information on social media - “FDA approves Hemlibra, a new treatment to prevent bleeding in people w/ hemophilia A and Factor VIII inhibitors“- HCP